TD Cowen lowered the firm’s price target on Sage Therapeutics (SAGE) to $9 from $10 and keeps a Hold rating on the shares. The firm noted they announced dalzanemdor failed to meet the 1 o EP of change from BL on the Symbol Digit Modalities Test at D84 in the Ph2 Huntington s cognitive impairment study. No stat sig or clinically meaningful differences were seen on secondary endpoints.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics price target lowered to $4 from $7 at BofA
- RBC upgrades Sage to Sector Perform with negative thesis played out
- Sage Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
- Sage Therapeutics reported another clinical setback, says H.C. Wainwright
- Sage Therapeutics reports results from Phase 2 DIMENSION Study